*Dear Editor,*

The rapidly spreading COVID-19 pandemic resulted in more than 8.5 million cases diagnosed and 450,000 deaths on June 20th, 2020. As described with other coronaviruses, SARS-CoV-2 was first expected to induce a monophasic disease with at least transient immunity.[@bib0001] ^,^ [@bib0002] Nevertheless, rare cases of suspected COVID-19 "recurrence" or "reactivation" have been reported, including the description by Ye & Colleagues in this journal of 5 patients with suspected SARS-CoV-2 reactivation after home discharge.[@bib0003], [@bib0004], [@bib0005], [@bib0006]

Similarly, the COCOREC (Collaborative study COvid RECurrences) study aimed at summarizing clinical and virological data of patients presenting a second confirmed COVID-19 episode, at least 21 days after the first onset, and after a symptom-free interval \[oxygen-free and discharge from acute-care unit (ACU), or return to usual clinical state\]. Cases were collected retrospectively at a multicenter observational level through the COCLICO (COllaborative CLInician COVID-19) French study group meeting. A COVID-19 episode was defined by (*i*) at least one recent major clinical sign of COVID-19 including fever or chills, febrile flu-like-syndrome, dyspnoea, anosmia, or dysgeusia; and (*ii*) a positive SARS-CoV-2 RT-PCR test. Patients were not included if a differential diagnosis (amongst which bacterial, fungal or other viral superinfection, thrombo-embolic complication, secondary organizing pneumonia or interstitial lung disease) could explain the symptom recurrence. After information, all patients agreed with the use of their anonymous medical data. The study has been approved by the Ethic Committee of French Speaking Society of Infectious Disease (CER-MIT), number 2020-0503 COVID.

Between April 6th and May 14th, 2020, 11 patients were identified (sex ratio M/F 1.2, median age 55, range \[19--91\] years). The median duration of symptoms was 18 \[13--41\] days for the first episode and 10 \[7--29\] days for the second one for the 7 patients who eventually recovered. Epidemiological and clinical data are summarized in [Table 1](#tbl0001){ref-type="table"} .Table 1Clinical characteristics of COVID 19 first and 2nd episodes, from onset of first episode (D1) to last follow-up (home-care patients: patients1--4; hospitalized patients: patients 5--11).Table 1:Patients characteristicsFirst episode2nd episodeCaseAgeSexPast medical historyClinical characteristicsTreatments1st Clinical cure2nd ep onsetClinical characteristicsTreatmentsDuration of 2nd episode (days)Outcome119FNone (HCW)FLS with no fever-cough-dyspnoea-AO-DG -headache-diarrhoea- otalgia-NoneD18D26FLS-cough-dyspnoea -chest painNoneon-goinghome care232FNone (HCW)Cough-AO-myalgia-headacheNoneD29D36FLSNone10cured333FFirst trimester pregnancy (HCW)Myalgia-headache-fatigue-nasal congestion-sore throatNoneD13D27Fatigue-nasal congestion-sore throat-chillsNone8cured443MNone (HCW)FLS-AO- headacheNoneD14D24Cough-AO-myalgia headache-diarrhoea-fatigueNone29cured585MBronchiectasis - CHD - pace maker - arrhythmiaFever-cough-dyspnoea-fatigue-confusion-fallsO2, ATBD17D44Cough-dyspnoea-fatigue-chest pain-confusion-acute heart failureO26cured654MHTFever-cough-dyspnoea -severe ARDS-fatigueICU, OTI, ATB, LPV/rtv, CTSD41D45Cough-dyspnoea-diarrhoea-ARDS-fatigueICU, OTI, ECMO, ATB34death791FCHD - HT-CVD- atherosclerosis- arrhythmia- DMFever-dyspnoea-fatigue-pleural & pericardial effusionO2, ATB, CTSD13D25Dyspnoea-fatiguenone9cured855MCLD, cirrhosis Child CFever-headache-fatigueATBD21D27Dyspnoea-headache-diarrhoea -fatigueICU-HFNIV-OTI ATB20cured972MAnti MAG neuropathy (rituximab, bendamustine)Fever- cough- dyspnoea-worsening neuropathyO2, ATBD21D27Fever- cough- dyspnoea -fatigue -- worsening neuropathyICU-HFNIV-OTI, ATB remdesivir29death1073MDLBCL (chemotherapy [d]{.smallcaps}-22)Fever-fatigue-abdominal cutaneous rashATBD13D24Fever-dyspnoea-fatigueO2, ATB, CTS [\*](#tb1fn1){ref-type="table-fn"}17cured1184FCLD / O2T -- mild CRD - CHD arrhythmia/ATC - valvulopathy - atherosclerosis - DMFever-cough-dyspnoea-AO-fatigueO2, curative ATC, ATB + CTSD23D49Fever-cough-dyspnoea-fatigueO2, HFNIV, ATB,tocilizumab, CTS curative ATC30death[^2][^3]

Four healthcare workers (patients 1--4, median age 32.5 \[19--43\] years) without significant comorbidity had a first mild COVID-19 episode with a complete recovery: three returned to work in COVID units, one had possible COVID re-exposure at home (patient 2). All of them experienced a clinical relapse requiring sick-leave but no hospitalization after a median symptom-free interval of 9 \[7--14\] days.

In contrast, 7 older comorbid patients (patients 5--11, median age 73 \[54--91\] years) required ACU hospitalization for both episodes, with a clinical recovery of 11 \[4--27\] days in the interval. During the first episode, one patient received lopinavir, and three corticosteroids. Six of them required oxygen therapy again during the second episode. Two patients died of ARDS recurrence and another of chronic right heart failure worsening.

All patients had a positive SARS-CoV-2 RT-PCR test in respiratory samples for both episodes ([Table 2](#tbl0002){ref-type="table"} ). They all showed CT scan signs of acute COVID-19 during the second episode, worsening for 4 in 7 when comparison available, including a case of pulmonary embolism without sign of superinfection and no differential diagnosis (supplementary Table). A SARS-CoV-2 serology was available after D21 for nine patients: five were positive, one slightly positive and three negative. A viral culture was performed on Vero E6 cells from naso-pharyngeal swabs of two patients during the second episode; one was positive with a typical cytopathic effect of SARS-CoV-2 and confirmed by RT-PCR; after sequencing, the strain was shown to belong to the B2 European lineage (Rambaut et al., bioRxiv preprint, doi: <https://doi.org/10.1101/2020.04.17.046086>).Table 2Laboratory findings of COVID 19 first and 2nd episodes, from onset of first episode (D1) to last follow-up.(home-care patients: patients1--4; hospitalized patients: patients 5--11).Table 2:First episode (onset = D1)No symptom2nd episodeCaseBlood testsSARS CoV2 PCRMinimal CRP Maximal L PCR if availableBlood testsSARS CoV2 PCRSerologyDays from onsetCT if available [\*](#tb2fn1){ref-type="table-fn"}Days from 1st onsetCT if available [\*](#tb2fn1){ref-type="table-fn"}Days from 1st onsetResults1NAD2E 18 - N22 - RdRP 19NANAD29E 35 - IP2 37 - IP4 42D58POSITIVE total Ig2NAD18E 23,9- N NA - RdRP 23,6NANAD36 D55E 31,5- N NA - RdRP 30,3 NEGATIVENANA3NAD330,5NAL 1800D2832,7D27POSITIVE IgG IgM4NAD3POSITIVE, CT NANAL 1300 Eo 90CRP 1D3821.5D31, 45slighly POSITIVE IgG, NEGATIVE IgM5L 290 Eo 0 CRP 33D1E8 - N11- RdRP 12L 870 CRP 17 PCR D36 : + E35L700 Eo 30 CRP 15D46E 33 - N 33 - RdRP 32 Viral culture NEGATIVENANA6L 690 CRP 365D16 D 38, 44IP2 29,4 - IP4 29.9 NEGATIVEL 2750 CRP 28L 690 Eo 50 CRP 247D45IP2 38.3 - IP4 36.2D31POSITIVE IgG IgM7L 720 Eo 10 CRP 143D3ORF1 18.7 - N 18.1L 1500 CRP 34L 1000 Eo 160 CRP 188D26ORF1 29,7D27POSITIVE IgG IgM8L 629 Eo 0 CRP 74D616L 1400 CRP 33L 800 Eo 10 CRP 73D31POSITIVE, CT NAD27 D47Ambiguous POSITIVE IgG9L 630 Eo 260 CRP 39D7POSITIVE, CT NAL 750 Eo 90 CRP 8L 360 Eo 0 CRP 85D 23, 32, 36POSITIVE, CT NAD41NEGATIVE10L 60 Eo 0 CRP 112.8D617 Cutaneous PCR negL 80 CRP 18L 60 Eo 30 CRP 160D3518D25NEGATIVE11L 770 CRP 88D11IP4 31L 1180 CRP 4.2L 480 CRP 346D50IP4 16,7 Viral culture POSITIVED53NEGATIVE[^4][^5]

Immunity to SARS-CoV-2 involves both cell-mediated and humoral responses, but its protective role from re-infection along with definitive viral clearance is uncertain.[@bib0007] Our case series of 11 patients having experienced two separate symptomatic COVID-19 episodes, associated with viral detection and no evidence for a differential diagnosis, raises two pathophysiological hypotheses underlying these recurrences: viral reinfection or viral reactivation from sanctuaries. In the case of healthy healthcare workers with mild symptoms at both episodes, a re-infection due to the prolonged exposition can be supposed, given the fact that the immune response may faint in this young population with no invasive infection.[@bib0008] The second group included vulnerable persons less likely to have met the virus again and having presented two repeated episodes of hypoxemic pneumonia, fatal in three cases. Recurrence might have occurred due to a suboptimal control of the SARS-CoV-2 infection, allowing a second episode of viral replication.

COVID-19 recurrences should be differentiated from secondary complications such as pulmonary embolism or super infection[@bib0005] or persistence of traces of viral RNA that can be detected in respiratory samples up to 6 weeks after onset of symptoms in clinically-cured patients.[@bib0009]

Immunosuppressive factors such as drugs or pathological conditions could contribute to impair viral clearance and favour SARS-CoV-2 reactivation.[@bib0010] Three of the 7 severe patients of our series, and 3 of 4 patients reported by Ye[@bib0003] received corticosteroids during the first episode. Furthermore, from our 3 patients who developed no SARS-CoV-2 antibodies more than 21 days after severe symptoms, two received recent chemotherapy and/or rituximab.

An inflammatory rebound triggered by an inappropriate immune response could constitute an alternative explanation to the recurrence of clinical symptoms. Yet, the facts that viral RNA was detected in all patients -some of them with low cycle threshold- and that a viral strain could be cultured during the second episode for one of them rather support re-infection or virus replication\'s rebound.

This work has some limitations. In addition to the limited number of observations, the cure between episodes was only clinically-defined (except for patient 6) because iterative RT-PCR controls were not recommended by French guidelines. Finally, viral culture could be performed only for two patients, with no phylogenic sequence comparison at this time.

In conclusion, the fact that patients could experience re-activation of a long-lasting virus carriage or might be re-infected, as well as potential long-term effects of drugs or diseases that hamper the immune response, constitutes a substantial point of vigilance for the management of the pandemic at the individual and collective levels. Studies including genomic comparisons of viral strains involved in both episodes, determination of RNA infectivity by viral culture, as well as assessment of innate and adaptive immunity and monitoring inflammatory targets, would be of great value for further understanding the underlying pathophysiology of these COVID-19 recurrences.
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[^1]: all the authors contributed equally to this article.

[^2]: Abbreviations : ATB : antibiotics - AO : anosmia -- ATC : anticoagulation - CHD : Chronic Heart Disease- CLD : Chronic Lung Disease- CRD : Chronic Renal Disease -- CVD : CerebroVascular Disease -- CTS : corticosteroids DM : Diabetes Mellitus -- DG : dysgeusia - DLBCL : Diffuse Large B Cell Lymphoma -- ECMO : extra-corporeal membrane oxygenation -- FLS : Flu Like Syndrome (= fever + myalgia + fatigue +/- sore throat, nasal congestion) - HT : hypertension -- HCW : Health Care Worker - HFNIV: High Flow Non Invasive Ventilation - ICU : Intensive Care Unit -LPV/rtv : lopinavir/ritonavir -- NA : Non Available - OTI : Oro-Tracheal Intubation -- O2 : oxygen therapy.

[^3]: No improvement after 7 days of piperacillin-tazobactam ; apyrexia 4 days after pip-taz stop and before linezolid.

[^4]: L : lymphocytes (per mm^3^ )-- Eo = Eosinophils polymorphonuclar leukocytes (per mm^3^)~-~ CRP : C Reactive Protein (mg/l) NA: Non Available.

[^5]: SARS CoV2 Polymerase Chain Reaction: cycle threshold (CT), envelope gene (E), nucleocapsid gene (N), ARN polymerase gene (RdRP, IP2, IP4), specific Open Reading Frame (ORF)1.
